Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Coda Therapeutics Inc patents


Recent patent applications related to Coda Therapeutics Inc. Coda Therapeutics Inc is listed as an Agent/Assignee. Note: Coda Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Coda Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Coda Therapeutics Inc-related inventors


 new patent  Compositions and methods for immunomodulation

The present invention relates to modulation of the tumor microenvironment to increase cancer specific immune responses. Conjugates, nanoparticles and formulations of the present invention relieve the inhibitory effect induced by tumor cells, and enhance antitumor immunity. ... Coda Therapeutics Inc

 new patent  Compositions and methods for immuno-oncology therapies

The present invention relates to cancer immunotherapy. Conjugates and nanoparticles comprising active agents that can elicit a cancer specific immune response are provided. ... Coda Therapeutics Inc

 new patent  Sstr-targeted conjugates and particles and formulations thereof

Conjugates of an active agent such as dm1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. ... Coda Therapeutics Inc

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Coda Therapeutics Inc

Compositions and methods for directing proteins to specific loci in the genome

Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a fusion protein comprising a dna localization component and an effector molecule. ... Coda Therapeutics Inc

Compositions and methods including a recombinant human mab that promotes cns remyelination

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. ... Coda Therapeutics Inc

Methods and compositions for administration of trpv1 agonists

Compositions are provided that contain a trpv1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. ... Coda Therapeutics Inc

Methods of reducing extravasation of inflammatory cells

A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. ... Coda Therapeutics Inc

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Coda Therapeutics Inc

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. . ... Coda Therapeutics Inc

Hyperactive piggybac transposases

The present invention provides piggybac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.. . ... Coda Therapeutics Inc

Carbonate prodrugs and methods of using the same

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. ... Coda Therapeutics Inc

Compositions and methods of using chondroitinase abci mutants

One aspect of the present invention relates to mutants of chondroitinase abci. Such chondroitinase abci mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to uv light or heat. ... Coda Therapeutics Inc

Indoline compounds as granzyme b inhibitors

Granzyme b inhibitor compounds, compositions that include the compounds, and methods for using the compounds. The compounds of the invention have advantageous water solubility and effectively inhibit granzyme b.. ... Coda Therapeutics Inc

03/01/18 / #20180055909

Method for achieving desired glial growth factor 2 plasma levels

The present invention relates to administering glial growth factor 2 (ggf2) to a patient in need thereof, to achieve serum levels of ggf2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the ggf2 is administered to promote myelination in the patient.. ... Coda Therapeutics Inc

02/01/18 / #20180028610

Methods for detecting cardiac damage

The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. ... Coda Therapeutics Inc

02/01/18 / #20180028513

Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.. . ... Coda Therapeutics Inc

01/25/18 / #20180021454

Targeted conjugates encapsulated in particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. ... Coda Therapeutics Inc

01/04/18 / #20180000959

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. ... Coda Therapeutics Inc

11/23/17 / #20170335311

Chimeric protein

A chimeric protein is disclosed for promoting repair and regeneration of neurons damaged by disease or physical injury wherein the chimeric protein is a combination of a first polypeptide possessing matrix modification activity and a second polypeptide possessing regenerating activity for neural cells.. . ... Coda Therapeutics Inc

11/23/17 / #20170333410

Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use

The present invention is directed to therapeutic pharmaceutical compositions of 1-methyl-2′, 6′-pipecoloxylidide or it pharmaceutically acceptable salts for application to the skin and the use thereof.. . ... Coda Therapeutics Inc

11/09/17 / #20170319562

Compositions and methods for extended therapy with aminopyridines

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.. . ... Coda Therapeutics Inc

10/05/17 / #20170281608

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. . ... Coda Therapeutics Inc

09/28/17 / #20170273960

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Coda Therapeutics Inc

09/21/17 / #20170266171

Durable treatment with 4-aminopyridine in patients with demyelination

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as ms.. . ... Coda Therapeutics Inc

09/07/17 / #20170252406

Compositions and methods for treatment during non-acute periods following cns neurological injury

This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.. . ... Coda Therapeutics Inc

08/24/17 / #20170240905

Impaired wound healing composition and treatments

Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.. . ... Coda Therapeutics Inc

08/24/17 / #20170238866

Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation

Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.. ... Coda Therapeutics Inc

08/03/17 / #20170218014

Azaindoline compounds as granzyme b inhibitors

Azaindoline compounds as granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.. ... Coda Therapeutics Inc

07/27/17 / #20170209608

Cyclic urea compounds as granzyme b inhibitors

An ultraviolet (uv) disinfection unit for disinfecting catheter line connections is provided. The unit can be used to disinfect solution set and transfer set catheters used for peritoneal dialysis. ... Coda Therapeutics Inc

07/27/17 / #20170209422

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Coda Therapeutics Inc

07/27/17 / #20170209421

Sustained release aminopyridine composition

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.. . ... Coda Therapeutics Inc

07/06/17 / #20170189469

Medical devices

Medical devices comprising an anti-connexin agent suitable for introduction into a subject.. . ... Coda Therapeutics Inc

06/15/17 / #20170166874

Hyperactive piggybac transposases

The present invention provides piggybac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.. . ... Coda Therapeutics Inc

06/15/17 / #20170165244

Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine

Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.. . ... Coda Therapeutics Inc

06/01/17 / #20170151339

Targeted conjugates and particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. ... Coda Therapeutics Inc

05/18/17 / #20170137799

Proteoglycan degrading mutants for treatment of cns

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“cns”) injury or disease.. . ... Coda Therapeutics Inc

04/27/17 / #20170114149

Methods and compositions for in vivo non-covalent linking

Disclosed are methods of facilitating the interaction of a first and a second component, the method including the use of an antibody fragment and an epitope tag. The antibody fragment may be bound to a first component, while the epitope tag may be bound to a second component. ... Coda Therapeutics Inc

04/20/17 / #20170107541

A method for directing proteins to specific loci in the genome and uses thereof

Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a dna localization component and an effector molecule, wherein the dna localization component and the effector molecule are capable of being operatively linked via a non-covalent linkage.. ... Coda Therapeutics Inc

04/06/17 / #20170095569

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. ... Coda Therapeutics Inc

03/16/17 / #20170071924

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.. ... Coda Therapeutics Inc

03/02/17 / #20170056468

Treatment of resistant lesions

Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.. ... Coda Therapeutics Inc

03/02/17 / #20170056385

Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to prove the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. . ... Coda Therapeutics Inc

02/09/17 / #20170035742

Durable treatment with 4-aminopyridine in patients with demyelination

Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as ms.. . ... Coda Therapeutics Inc

02/02/17 / #20170028038

Compositions and methods of using chondroitinase abci mutants

The present disclosure relates to protein and nucleic acid mutants of chondroitinase abci. Such nucleic acid mutants encode for chondroitinase abci mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including uv light or heat. ... Coda Therapeutics Inc

01/19/17 / #20170015707

Covalent granzyme b inhibitors

Covalent granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. A method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.. ... Coda Therapeutics Inc

01/19/17 / #20170015706

Proline compounds as granzyme b inhibitors

Proline compounds as granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.. ... Coda Therapeutics Inc

01/19/17 / #20170015705

Pyrrole compounds as granzyme b inhibitors

Pyrrole compounds as granzyme b inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.. ... Coda Therapeutics Inc

01/12/17 / #20170009222

Compositions and methods of using chondroitinase abci mutants

One aspect of the present invention relates to mutants of chondroitinase abci. Such chondroitinase abci mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to uv light or heat. ... Coda Therapeutics Inc

01/12/17 / #20170008916

Carbonate prodrugs and methods of using the same

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. ... Coda Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Coda Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Coda Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###